Loading...
Loading...
ZVSA| Name | Value |
|---|---|
| Revenues | 15.6K |
| Cost of Revenue | 2.6K |
| Gross Profit | 13.0K |
| Operating Expense | 1,773.6K |
| Operating I/L | -1,776.2K |
| Other Income/Expense | -12,158.4K |
| Interest Income | 0.0K |
| Pretax | -13,934.6K |
| Income Tax Expense | -596.1K |
| Net Income/Loss | -13,338.5K |
ZyVersa Therapeutics, Inc. is a clinical stage biopharmaceutical company specializing in the development and commercialization of products for the treatment of renal and inflammatory diseases. The company's primary focus is on VAR 200, a cholesterol efflux mediator designed to address focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease, as well as IC 100, a novel inflammasome ASC inhibitor targeting a range of inflammatory diseases.
